 Théa
		
												Théa
									
	Sepul Bio, an innovative business unit of Théa, Doses First Participant in Phase 3 HYPERIONclinical trial of sepofarsen for CEP290-associated Leber Congenital Amaurosis Type 10
Sepul Bio: Théa’s Innovative Unit Doses First in Phase 3 HYPERION Trial for LCA10
10/1/25
 
		 
		 
		 
		 
					
					 
					
					 
					
					 
					
					 
     
     
		